Clinical trials: Uveal Melanoma
Melanoma
Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
This is a phase I/II clinical trial of a single dose of CD40L-augmented TIL administered in patients with advanced melanoma (Cohort 1: Cutaneous acral melanoma, cutaneous non-acral melanoma, (n=26); Cohort 2: Mucosal melanoma…
- Trial name
- NCT06961357
- Testing
- Cyclophosphamide, Fludarabine, Interleukin-2
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Relapsed Neuroblastoma, Refractory Neuroblastoma
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
This study is for patients with neuroblastoma, sarcoma, uveal melanoma, breast cancer, or another cancer that expresses a substance on the cancer cells called GD2.
- Conditions
- Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma, Relapsed Ewing Sarcoma
- Trial name
- NCT03635632
- Testing
- C7R-GD2.CART cells
- Where
- 2 sites in United States
- Volunteers
- 94 people
- Sponsor
- Baylor College of Medicine
Metastatic Uveal Melanoma, Cutaneous Melanoma
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including…
- Conditions
- Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
- Trial name
- NCT03947385
- Testing
- IDE196, Binimetinib, Crizotinib
- Where
- 15 sites in United States, Australia and 1 more
- Volunteers
- 336 people
- Sponsor
- IDEAYA Biosciences
Metastatic Uveal Melanoma
A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma
Doctors usually treat uveal melanoma with radiotherapy or surgery. But if this cancer spreads, it is more difficult to treat. Doctors usually treat uveal melanoma that has spread with a chemotherapy called dacarbazine, but they…
- Trial name
- SUAVE (NCT01551459)
- Testing
- Dacarbazine, Sunitinib
- Where
- United Kingdom
- Volunteers
- 124 people
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
Mestastatic Uveal Melanoma
Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma
Uveal melanoma (UM) is a rare type of melanoma, with an incidence of 4.4 cases per million in Europe each year. During recent years, different treatment approaches have been tested in patients with metastatic UM.
- Trial name
- NEO-TB (NCT07057596)
- Testing
- Tebentafusp
- Where
- 4 sites in Germany, Spain
- Volunteers
- 19 people
- Sponsor
- Grupo Español Multidisciplinar de Melanoma
Melanoma (Excluding Uveal Melanoma)
HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma（FASTIL-Mela02）
This is a multicenter, randomized controlled, open-label Phase II clinical study designed to evaluate the efficacy and safety of HS-IT101 Injection versus the investigator's choice of chemotherapy in participants with advanced…
- Trial name
- NCT07406724
- Testing
- Tumor Tissue Sampling, Lymphodepletion Conditioning, Infusion of HS-IT101 Injection
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Hangzhou Huasai Biomedicine Co., Ltd.
Metastatic Melanoma, Mucosal Melanoma
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
This randomized phase II trial studies how well nab-paclitaxel and bevacizumab or ipilimumab works as first-line therapy in treating patients with stage IV melanoma that cannot be removed by surgery.
- Conditions
- Metastatic Melanoma, Mucosal Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7
- Trial name
- NCT02158520
- Testing
- Bevacizumab, Ipilimumab, Laboratory Biomarker Analysis
- Where
- 13 sites in United States
- Volunteers
- 24 people
- Sponsor
- Academic and Community Cancer Research United
Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors
Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma
Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrades arginine. ADI has been formulated with polyethylene glycol, and has been used to treat patients that have cancers…
- Trial name
- NCT01665183
- Testing
- ADI-PEG 20
- Where
- 2 sites in United States, Taiwan
- Volunteers
- 8 people
- Sponsor
- Polaris Group
Cutaneous Melanoma, Uveal Melanoma
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
This is a first-in-human, multi-center clinical study to determine the safety, Maximum Tolerated Dose (MTD) and/or Optimal Biological Dose (OBD) as well as the optimal schedule for intravenous (IV) and/or subcutaneous (SC)…
- Conditions
- Cutaneous Melanoma, Uveal Melanoma, Mucosal Melanoma
- Trial name
- NCT04551352
- Testing
- RO7293583, Tocilizumab, Obinutuzumab
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver
Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
The purpose of this study is to determine the effects (good and bad) that Tebentafusp in combination with Yttrium-90 (Y-90) radioembolization has on patients with metastatic uveal melanoma that has spread to the liver.
- Trial name
- NCT06627244
- Testing
- Tebentafusp, TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Miami
Metastatic Esophageal, Gastric Cancer
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
This is an investigator-initiated industry-supported phase 1 clinical trial conducted in the phase 1 clinic at The University of Texas MD Anderson Cancer Center who will hold the Investigational New Drug (IND).
- Conditions
- Metastatic Esophageal, Gastric Cancer, Metastatic Head and Neck Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT05075993
- Testing
- LVGN3616 + LVGN6051 + Nab-Paclitaxel, LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide, LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel
- Where
- United States
- Volunteers
- 352 people
- Sponsor
- M.D. Anderson Cancer Center
Exudative Retinal Detachment and Uveal Melanoma
Dexamethasone Implant for Retinal Detachment in Uveal Melanoma
This is an investigator-initiated Phase I study of a single dose of an intravitreally-administered dexamethasone implant (Ozurdex™) in subjects with uveal melanomas (UM) and exudative retinal detachments (ERD: build-up of fluid…
- Trial name
- NCT04082962
- Testing
- Dexamethasone intravitreal implant
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Ivana K. Kim
Choroidal Melanoma, Indeterminate Lesions
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
- Conditions
- Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
- Trial name
- CoMpass (NCT06007690)
- Testing
- Bel-sar, Suprachoroidal Microinjector, Infrared Laser
- Where
- 53 sites in United States, Australia and 12 more
- Volunteers
- 108 people
- Sponsor
- Aura Biosciences
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
RATIONALE: Drugs used in chemotherapy, such as dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Recurrent Intraocular Melanoma
- Trial name
- NCT01100528
- Testing
- recombinant interferon alfa-2b, dacarbazine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Case Comprehensive Cancer Center
Metastatic Uveal Melanoma
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or…
- Trial name
- NCT05987332
- Testing
- IDE196, Crizotinib, Pembrolizumab
- Where
- 68 sites in United States, Australia and 11 more
- Volunteers
- 420 people
- Sponsor
- IDEAYA Biosciences
Metastatic Ocular Melanoma, Metastatic Uveal Melanoma
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
Patients in the study will be treated with Melphalan/HDS and will receive up to 6 total treatments. This study will evaluate the safety and effects of the treatment.
- Trial name
- NCT05022901
- Testing
- Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS)
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Delcath Systems Inc.
Choroidal Melanoma, Indeterminate Lesions of Eye
A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
The purpose of this observational research study is to follow participants who have been treated with bel-sar while participating in a previous Aura Biosciences clinical research study to assess the long-term safety and…
- Trial name
- NCT03941379
- Where
- 16 sites in United States
- Volunteers
- 63 people
- Sponsor
- Aura Biosciences
Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor…
- Conditions
- Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation
- Trial name
- NCT03611868
- Testing
- Phase 1b: APG-115+pembrolizumab
- Where
- 21 sites in United States, Australia
- Volunteers
- 230 people
- Sponsor
- Ascentage Pharma Group Inc.
Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
This phase II trial is studying how well vorinostat works in treating patients with metastatic or unresectable melanoma. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by…
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Uveal Melanoma
- Trial name
- NCT00121225
- Testing
- vorinostat
- Where
- 5 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Uveal Melanoma
Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma
Neoadjuvant RBP-01 in patients with primary uveal melanoma.
- Trial name
- Uveal Melanoma (NCT07747935)
- Testing
- RBP-01
- Volunteers
- 30 people
- Sponsor
- ReBio Pharma